These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 29985080)

  • 1. Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial.
    Brahe CH; Østergaard M; Johansen JS; Defranoux N; Wang X; Bolce R; Sasso EH; Ørnbjerg LM; Hørslev-Petersen K; Stengaard-Pedersen K; Junker P; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Lottenburger T; Ammitzbøll C; Jørgensen A; Krintel SB; Raun J; Hetland ML
    Scand J Rheumatol; 2019 Jan; 48(1):9-16. PubMed ID: 29985080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating serum interleukin-6, serum chitinase-3-like protein-1, and plasma vascular endothelial growth factor are not predictive for remission and radiographic progression in patients with early rheumatoid arthritis: post-hoc explorative and validation studies based on the CIMESTRA and OPERA trials.
    Brahe CH; Dehlendorff C; Østergaard M; Johansen JS; Ørnbjerg LM; Hørslev-Petersen K; Stengaard-Pedersen K; Junker P; Ellingsen T; Lindegaard H; Hansen I; Lottenburger T; Jacobsen S; Jurik AG; Hetland ML
    Scand J Rheumatol; 2018 Jul; 47(4):259-269. PubMed ID: 29336711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum 14-3-3η as predictor of clinical remission and progression of structural damage in early rheumatoid arthritis following a treat-to-target strategy in a randomized controlled trial.
    Raft MB; Hetland ML; Brahe CH; Hørslev-Petersen K; Midtbøll Ørnbjerg L; Junker P; Biln N; Stengaard-Pedersen K; Østergaard M
    Scand J Rheumatol; 2023 Jul; 52(4):342-352. PubMed ID: 35833274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of multi-biomarker disease activity score and other risk factors with radiographic progression in an observational study of patients with rheumatoid arthritis.
    Li W; Sasso EH; van der Helm-van Mil AH; Huizinga TW
    Rheumatology (Oxford); 2016 Feb; 55(2):357-66. PubMed ID: 26385370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial.
    Hambardzumyan K; Bolce R; Saevarsdottir S; Cruickshank SE; Sasso EH; Chernoff D; Forslind K; Petersson IF; Geborek P; van Vollenhoven RF
    Ann Rheum Dis; 2015 Jun; 74(6):1102-9. PubMed ID: 24812287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of a multi-biomarker disease activity score in rheumatoid arthritis by comparison with magnetic resonance imaging, computed tomography, ultrasonography, and radiography parameters of inflammation and damage.
    Krabbe S; Bolce R; Brahe CH; Døhn UM; Ejbjerg BJ; Hetland ML; Sasso EH; Chernoff D; Hansen MS; Knudsen LS; Hansen A; Madsen OR; Hasselquist M; Møller J; Østergaard M
    Scand J Rheumatol; 2017 Sep; 46(5):353-358. PubMed ID: 27682742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulated baseline plasma CCL19 and CCR7 cell-surface expression on monocytes in early rheumatoid arthritis normalized during treatment and CCL19 correlated with radiographic progression.
    Ellingsen T; Hansen I; Thorsen J; Møller BK; Tarp U; Lottenburger T; Andersen LS; Skjødt H; Pedersen JK; Lauridsen UB; Svendsen A; Lindegaard H; Jacobsen S; Østergaard M; Vestergaard A; Jurik AG; Junker P; Christensen AF; Hetland ML; Hørslev-Petersen K; Stengaard-Pedersen K
    Scand J Rheumatol; 2014; 43(2):91-100. PubMed ID: 23980529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression.
    van der Helm-van Mil AH; Knevel R; Cavet G; Huizinga TW; Haney DJ
    Rheumatology (Oxford); 2013 May; 52(5):839-46. PubMed ID: 23287359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes.
    Bouman CAM; van der Maas A; van Herwaarden N; Sasso EH; van den Hoogen FHJ; den Broeder AA
    Rheumatology (Oxford); 2017 Jun; 56(6):973-980. PubMed ID: 28339738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies.
    Roodenrijs NMT; de Hair MJH; Wheater G; Elshahaly M; Tekstra J; Teng YKO; Lafeber FPJG; Hwang CC; Liu X; Sasso EH; van Laar JM
    Arthritis Res Ther; 2018 Nov; 20(1):256. PubMed ID: 30458871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA).
    Hetland ML; Ejbjerg B; Hørslev-Petersen K; Jacobsen S; Vestergaard A; Jurik AG; Stengaard-Pedersen K; Junker P; Lottenburger T; Hansen I; Andersen LS; Tarp U; Skjødt H; Pedersen JK; Majgaard O; Svendsen AJ; Ellingsen T; Lindegaard H; Christensen AF; Vallø J; Torfing T; Narvestad E; Thomsen HS; Ostergaard M;
    Ann Rheum Dis; 2009 Mar; 68(3):384-90. PubMed ID: 18388160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies.
    Curtis JR; Brahe CH; Østergaard M; Lund Hetland M; Hambardzumyan K; Saevarsdottir S; Wang X; Flake Ii DD; Sasso EH; Huizinga TW
    Curr Med Res Opin; 2019 Sep; 35(9):1483-1493. PubMed ID: 30777458
    [No Abstract]   [Full Text] [Related]  

  • 13. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
    Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Okada T; van der Heijde D; Miyasaka N; Koike T
    Ann Rheum Dis; 2016 Jan; 75(1):75-83. PubMed ID: 26139005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiographic progression and remission rates in early rheumatoid arthritis - MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial.
    Hetland ML; Stengaard-Pedersen K; Junker P; Østergaard M; Ejbjerg BJ; Jacobsen S; Lottenburger T; Hansen I; Tarp U; Andersen LS; Svendsen A; Pedersen JK; Lauridsen UB; Ellingsen T; Lindegaard H; Pødenphant J; Vestergaard A; Jurik AG; Hørslev-Petersen K;
    Ann Rheum Dis; 2010 Oct; 69(10):1789-95. PubMed ID: 20444751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice.
    Hirata S; Li W; Kubo S; Fukuyo S; Mizuno Y; Hanami K; Sawamukai N; Yamaoka K; Saito K; Defranoux NA; Tanaka Y
    Mod Rheumatol; 2016 Nov; 26(6):850-856. PubMed ID: 26873570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial.
    Ørnbjerg LM; Østergaard M; Jensen T; Hørslev-Petersen K; Stengaard-Pedersen K; Junker P; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Lottenburger T; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Hetland ML; ; Slot O; Nielsen LK; Skjødt H; Majgaard O; Lorenzen T; Horn HC; Kowalski M; Johansen IL; Pedersen PM; Manilo N; Bliddal H
    Clin Rheumatol; 2017 Apr; 36(4):781-789. PubMed ID: 27921185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure.
    Hambardzumyan K; Saevarsdottir S; Forslind K; Petersson IF; Wallman JK; Ernestam S; Bolce RJ; van Vollenhoven RF
    Arthritis Rheumatol; 2017 May; 69(5):953-963. PubMed ID: 27992691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.
    Wells AF; Westhovens R; Reed DM; Fanti L; Becker JC; Covucci A; Keystone EC
    J Rheumatol; 2011 Nov; 38(11):2362-8. PubMed ID: 21885491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multibiomarker disease activity score for rheumatoid arthritis predicts radiographic joint damage in the BeSt study.
    Markusse IM; Dirven L; van den Broek M; Bijkerk C; Han KH; Ronday HK; Bolce R; Sasso EH; Kerstens PJ; Lems WF; Huizinga TW; Allaart CF
    J Rheumatol; 2014 Nov; 41(11):2114-9. PubMed ID: 25128518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-cyclic citrullinated peptide antibodies, 28-joint Disease Activity Score, and magnetic resonance imaging bone oedema at baseline predict 11 years' functional and radiographic outcome in early rheumatoid arthritis.
    Hetland ML; Østergaard M; Stengaard-Pedersen K; Junker P; Ejbjerg B; Jacobsen S; Ellingsen T; Lindegaard H; Pødenphant J; Vestergaard A; Jurik AG; Krogh NS; Hørslev-Petersen K;
    Scand J Rheumatol; 2019 Jan; 48(1):1-8. PubMed ID: 30101636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.